AID = automated insulin delivery; CGM = continuous glucose monitoring; DKA = diabetetic ketoacidosis; iCGM = integrated CGM.
*Separate Follow app and internet connection required.
BRIEF SAFETY STATEMENT
Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.
1 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K213919. Published December 7, 2022. https://www.accessdata.fda.gov/cdrh_docs/reviews/K213919.pdf. 2 U.S. Food and Drug Administration, 510(k) Substantial Equivalence Determination Decision Summary, K222447. Published March 3, 2023. https://www.accessdata.fda.gov/cdrh_docs/reviews/K222447.pdf. 3 Peacock S, et al. Diabetes Ther. 2023;14(5):839-855. 4 Dexcom, data on file, 2023. 5 Russell SJ, et al. N Engl J Med. 2022;387(13):1161-1172.
Dexcom, Dexcom Share, and Dexcom Follow are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
©2023 Dexcom, Inc. All rights reserved. MAT-0575 V1.0
Tandem Diabetes Care, the Tandem logo, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.
